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 2 
Abstract: 24 
We analyzed genetic data of 47,429 multiple sclerosis (MS) and 68,374 control subjects and 25 
establish a reference map of the genetic architecture of MS that includes 200 autosomal 26 
susceptibility variants outside the major histocompatibility complex (MHC), one chromosome X 27 
variant, and 32 within the extended MHC. We used an ensemble of methods to prioritize 551 28 
putative susceptibility genes, that implicate multiple innate and adaptive pathways distributed 29 
across the cellular components of the immune system. Using expression profiles from purified 30 
human microglia, we observe enrichment for MS genes in these brain-resident immune cells, 31 
suggesting that these may have a role in targeting an autoimmune process to the central nervous 32 
system, although MS is most likely initially triggered by perturbation of peripheral immune 33 
responses. 34 
 35 
 36 
One Sentence Summary: We report a detailed genetic and genomic map of multiple sclerosis, 37 
and describe the role of putatively affected genes in the peripheral immune system and brain 38 
resident microglia.  39 
 3 
Introduction 40 
Over the last decade, elements of the genetic architecture of multiple sclerosis (MS) 41 
susceptibility have gradually emerged from genome-wide and targeted studies.(1-6) The role of 42 
the adaptive arm of the immune system, particularly its CD4+ T cell component has become 43 
clearer, with multiple different T cell subsets being implicated.(4) While the T cell component 44 
plays an important role, functional and epigenomic annotation studies have begun to suggest that 45 
other elements of the immune system may be involved as well.(7, 8) Here, we assemble available 46 
genome-wide MS data to perform a meta-analysis followed by a systematic, comprehensive 47 
replication effort in large independent sets of subjects. This effort has yielded a detailed genome- 48 
wide genetic map that includes the first successful evaluation of the X chromosome in MS, and 49 
provides a powerful platform for the creation of a detailed genomic map, outlining the functional 50 
consequences of most variants and their assembly into susceptibility networks (Fig. S1). 51 
Discovery and replication of genetic associations  52 
We organized available (1, 2, 4, 5) and newly genotyped genome-wide data in 15 data sets, 53 
totaling 14,802 subjects with MS and 26,703 controls for our discovery study (9) (Tables S1-S3). 54 
After rigorous per data set quality control, we imputed all samples using the 1000 Genomes 55 
European panel resulting in an average of 7.8 million imputed single nucleotide polymorphisms 56 
(SNPs) with minor allele frequency (MAF) of at least 1% (9). We then performed a meta- 57 
analysis, penalized for within-data set residual genomic inflation, to a total of 8,278,136 SNPs 58 
with data in at least two data sets (9). Of these, 26,395 SNPs reached genome-wide significance 59 
(p-value < 5x10-8; fixed effects inverse-variance meta-analysis) and another 576,204 SNPs had at 60 
least nominal evidence of association (5x10-8 > p-value < 0.05; fixed effects inverse-variance 61 
meta-analysis). In order to identify statistically independent SNPs in the discovery set and to 62 
prioritize variants for replication, we applied a genome partitioning approach (9). Briefly, we first 63 
excluded an extended region of ~12Mb around the major histocompatibility complex (MHC) 64 
locus to scrutinize this unique region separately (see below), and we then applied an iterative 65 
method to discover statistically independent SNPs in the rest of the genome using conditional 66 
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modeling. We partitioned the genome into regions by extracting ±1Mbs on either side of the most 67 
statistically significant SNP and repeating this procedure until there were no SNPs with a p- 68 
value<0.05 (fixed effects inverse-variance meta-analysis) left in the genome. Within each region 69 
we applied conditional modeling to identify statistically independent effects (Fig. S2). As a result, 70 
we identified 1,961 non-MHC autosomal regions that included 4,842 presumably statistically 71 
independent SNPs. We refer to these 4,842 prioritized SNPs as “effects”, assuming that these 72 
SNPs tag a true causal genetic effect. Of these, 82 effects were genome-wide significant in the 73 
discovery analysis, and another 125 had a p-value < 1x10-5 (fixed effects inverse-variance meta- 74 
analysis).  75 
In order to replicate these 4,842 effects, we analyzed two large-scale independent sets of data. 76 
First, we designed the MS Chip to directly replicate each of the prioritized effects (9) and, after 77 
stringent quality check (9) (Table S4), analyzed 20,360 MS subjects and 19,047 controls, which 78 
were organized in 9 data sets. Second, we incorporated targeted genotyping data generated using 79 
the ImmunoChip platform on an additional 12,267 MS subjects and 22,625 control subjects that 80 
had not been used in either the discovery or the MS Chip subject sets (Table S5).(3) Overall, we 81 
jointly analyzed data from 47,429 MS cases and 68,374 control subjects to provide the largest and 82 
most comprehensive genetic evaluation of MS susceptibility to date.   83 
For 4,311 of the 4,842 effects (89%) that were prioritized in the discovery analysis, we could 84 
identify at least one tagging SNP in the replication data (9) (Table S6). 156 regions had at least 85 
one genome-wide effect, and, overall, 200 prioritized effects reached a level of genome-wide 86 
significance (GW) in these 156 regions (Fig. 1). 62 of these 200 effects represent secondary, 87 
independent, effects that emerged from conditional modeling within a given locus (9) (Table S7, 88 
Fig. S3). The odds ratios (ORs) of these genome-wide effects ranged from 1.06 to 2.06, and the 89 
allele frequencies of the respective risk allele from 2.1% to 98.4% in the European samples of the 90 
1000 Genomes reference (mean: 51.3%, standard deviation: 24.5%; Table S8 and Fig. S4). 19.9% 91 
of regions (31 out of 156) harbored more than one statistically independent GW effect. One of the 92 
most complex regions was the one harboring the EVI5 gene that has been the subject of several 93 
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reports with contradictory results.(10-13) In this locus, we identified four statistically independent 94 
genome-wide effects, three of which were found under the same association peak (Fig. 2A), 95 
illustrating how our approach and the large sample size clarifies associations described in smaller 96 
studies and can facilitate functional follow-up of complex loci.  97 
We also performed a joint analysis of available data on sex chromosome variants (9), and we 98 
identified rs2807267 as genome-wide significant (ORT=1.07, p-value=6.86x10-9; fixed effects 99 
inverse-variance meta-analysis; Tables S9-S10). This variant lies within an enhancer peak 100 
specific for T cells and is 948bps downstream of the RNA U6 small nuclear 320 pseudogene 101 
(RNU6-320P), a component of the U6 small nuclear ribonucleoprotein (snRNP) that is part of the 102 
spliceosome and is responsible for the splicing of introns from pre-mRNA (14) (Fig. 2B). The 103 
nearest gene is VGLL1 (27,486bps upstream) that has been proposed to be a co-activator of 104 
mammalian transcription factors.(15) No variant in the Y chromosome had a p-value lower than 105 
0.05 (fixed effects inverse-variance meta-analysis).   106 
 The MHC was the first MS susceptibility locus to be identified, and prior studies have found 107 
that it harbors multiple independent susceptibility variants, including interactions within the class 108 
II HLA genes.(16, 17) We undertook a detailed modeling of this region to account for its long- 109 
range linkage disequilibrium and allelic heterogeneity using SNP data as well as imputed 110 
classical alleles and amino acids of the human leukocyte antigen (HLA) genes in the assembled 111 
data. We confirm prior MHC susceptibility variants (including a non-classical HLA effect located 112 
in the TNFA/LST1 long haplotype), and we extend the association map to uncover a total of 31 113 
statistically independent effects at the genome-wide level within the MHC (Fig. 3, Table S11). 114 
An interesting finding is that multiple HLA and nearby non-HLA genes have several independent 115 
effects that can now be identified due to our large sample, e.g. the HLA-DRB1 locus has six 116 
statistically independent effects. Another exciting finding involves HLA-B that also appears to 117 
harbor 6 independent effects on MS susceptibility. The role of the non-classical HLA and non- 118 
HLA genome in the MHC is also highlighted. One third (9 out of 31) of the identified variants lie 119 
within either intergenic regions or in a long-range haplotype that contains several non-classical 120 
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HLA and other non-HLA genes.(17) Recently, we reported an interaction between HLA- 121 
DRB1*15:01 and HLA-DQA1*01:01 by analyzing imputed HLA alleles.(16) Here we reinforce 122 
this analysis by analyzing SNPs, HLA alleles, and respective amino acids. We replicate the 123 
presence of interactions among class II alleles but note that the second interaction term, besides 124 
HLA-DRB1*15:01, can vary depending on the other independent variants that are included in the 125 
model. First, we found that there are interaction models of HLA-DRB1*15:01 with other variants 126 
in MHC that explain better the data than our previously reported HLA-DRB1*15:01/HLA- 127 
DQA1*01:01 interaction term (Fig. S5). Second, we observe that there is a group of HLA*DQB1 128 
and HLA*DQA1 SNPs, alleles, and amino acids that consistently rank amongst the best models 129 
with HLA-DRB1*15:01 interaction terms (Fig. S6). This group of HLA-DRB1*15:01-interacting 130 
variants is consistently identified regardless of the marginal effects of other statistically 131 
independent variants that are added in the model, implying that these interaction terms capture a 132 
different subset of phenotypic variance and can be explored after the identification of the 133 
marginal effects. Finally, we performed a sensitivity analysis by including interaction terms of 134 
HLA-DRB1*15:01 in each step and selecting the model with the lowest Bayesian information 135 
criterion (BIC), instead of testing only the marginal results of the variants as we did in the main 136 
analysis (classical model MHC analysis; Table S12). This sensitivity analysis also resulted in 32 137 
statistically independent effects with a genome-wide significant p-value (fixed effects inverse- 138 
variance meta-analysis; Table S12), of which one third (9 out of 32) were different than the ones 139 
in classical model MHC analysis. The main differences between the results of the two approaches 140 
were the inclusion of interaction of HLA-DRB1*15:01 and rs1049058 in step 3 and the stronger 141 
association of HLA*DPB1/2 effects over HLA*DRB1 effects in the sensitivity model (Tables 142 
S12-S13 and Fig. S6). Thus, overall, our MHC results are not strongly affected by the analytic 143 
model that we have selected. 144 
Characterization of non-genome wide effects  145 
The commonly used threshold of genome-wide significance (p-value = 5x10-8) has played an 146 
important role in making human genetic study results robust; however, several studies have 147 
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demonstrated that non-genome-wide effects explain an important proportion of the effect of 148 
genetic variation on disease susceptibility. (18, 19) More importantly, several such effects are 149 
eventually identified as genome-wide significant, given enough sample size and true effects.(3) 150 
Thus, we also evaluated the non-genome-wide effects that were selected for replication, have 151 
available replication data (n=4,111), but do not meet a standard threshold of genome-wide 152 
significance (p<5x10-8).  Specifically, we decided to stratify these 4,111 effects into 2 main 153 
categories (9): (1) suggestive effects (S, n=416), and (2) non-replicated effects (NR, n= 3,695). 154 
We used these categories in downstream analyses to further characterize the prioritized effects 155 
from the discovery study in terms of potential to eventually be replicated. We also included a 156 
third category: effects for which there were no data for replication in any of the replication sets 157 
(no data, ND, n=532). Furthermore, to add granularity in each category, we sub-stratified the 158 
suggestive effects into 2 groups: (1a) strongly suggestive (5 x10-8 > p-value <1x10-5; sS, n= 117; 159 
fixed effects inverse-variance meta-analysis) and (1b) underpowered suggestive (unS, n=299). Of 160 
these two categories of suggestive effects, the ones in the sS category have a high probability of 161 
reaching genome-wide significance as we increase our sample size in future studies (9) (Table 162 
S14). 163 
Heritability explained  164 
To estimate the extent to which we have characterized the genetic architecture of MS 165 
susceptibility with our 200 genome-wide non-MHC autosomal MS effects, we calculated the 166 
narrow-sense heritability captured by common variation (h2g), i.e. the ratio of additive genetic 167 
variance to the total phenotypic variance ().(18, 20) Only the 15 strata of data from the discovery 168 
set had true genome-wide coverage, and hence we used these 14,802 MS subjects and 26,703 169 
controls for the heritability analyses. The overall heritability estimate for MS susceptibility in the 170 
discovery set of subjects was 19.2% (95%CI: 18.5-19.8%). Heritability partitioning using minor 171 
allele frequency or p-value thresholds has led to significant insights in previous studies,(21) and 172 
we therefore applied a similar partitioning approach but in a fashion that took into consideration 173 
the study design and the existence of replication information from the 2 large-scale replication 174 
 8 
cohorts. First, we partitioned the autosomal genome into 3 components: i) the super extended 175 
MHC (SE MHC, see above), ii) a component with the 1,961 regions prioritized for replication 176 
(Regions), and iii) the rest of the genome that had a p-value>0.05 (fixed effects inverse-variance 177 
meta-analysis) in the discovery study (Non-associated regions). Then, we estimated the h2g that 178 
can be attributed to each component as a proportion of the overall narrow-sense heritability 179 
observed. The SE MHC explained 21.4% of the h2g, with the remaining 78.6% being captured by 180 
the second component (Fig. 4A). Then, we further partitioned the non-MHC component into one 181 
that captured all 4,842 statistically independent effects (Prioritized for replication), which 182 
explained the vast majority of the overall estimated heritability: 68.3%. The “Non-prioritized” 183 
SNPs in the 1,961 regions explained 11.6% of the heritability, which suggests that there may be 184 
residual LD with prioritized effects or true effects that have not yet been identified (Fig. 4B).  185 
We then used the replication-based categories described above to further partition the 186 
“Prioritized” heritability component, namely “GW”, “S”, “NR”, “ND” (Fig. 4C). The genome- 187 
wide effects (GW) captured 18.3% of the overall heritability. Thus, along with the contribution of 188 
the SE MHC (20.2% in the same model), we can now explain ~39% of the genetic predisposition 189 
to MS with the validated susceptibility alleles. This can be extended to ~48% if we include the 190 
suggestive (S) effects (9.0%). Interestingly the non-replicated (NR) effects captured 38.8% of the 191 
heritability, which could imply that some of these effects might be falsely non-replicated, i.e. that 192 
these are true effects that need further data to emerge robustly or that their effect may be true and 193 
present in only a subset of the data. However, few of the 3,695 NR effects would fall in either of 194 
the above two cases; the vast majority of these effects are likely to be false positive results.  195 
Functional implications of the MS loci, enriched pathways and gene-sets  196 
Next, we began to annotate the MS effects. To prioritize the cell types or tissues in which the 197 
200 non-MHC autosomal effects may exert their effect, we used two different approaches: one 198 
that leverages atlases of gene expression patterns and another that uses a catalog of epigenomic 199 
features such as DNase hypersensitivity sites (DHSs).(8, 9, 22-24) Significant enrichment for MS 200 
susceptibility loci was apparent in many different immune cell types and tissues, whereas there 201 
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was an absence of enrichment in tissue-level central nervous system (CNS) profiles (Fig. 5). An 202 
important finding is that the enrichment is observed not only in immune cells that have long been 203 
studied in MS, e.g. T cells, but also in B cells whose role has emerged more recently.(25) 204 
Furthermore, while the adaptive immune system has been proposed to play a predominant role in 205 
MS onset,(26) we now demonstrate that many elements of innate immunity, such as natural killer 206 
(NK) cells and dendritic cells also display strong enrichment for MS susceptibility genes. 207 
Interestingly, at the tissue level, the role of the thymus is also highlighted, possibly suggesting a 208 
role of genetic variation in thymic selection of autoreactive T cells in MS.(27) Public tissue-level 209 
CNS data – which are derived from a complex mixture of cell types - do not show an excess of 210 
MS susceptibility variants in annotation analyses. However, since MS is a disease of the CNS, we 211 
extended the annotation analyses by analyzing data generated from human iPSC-derived neurons 212 
as well as from purified primary human astrocytes and microglia (9). As seen in Fig. 6, 213 
enrichment for MS genes is seen in human microglia (p=5x10-14) but not in astrocytes or neurons, 214 
suggesting that the resident immune cells of the brain may also play a role in MS susceptibility. 215 
We repeated the enrichment analyses for the “S” and “NR” effects aiming to test whether 216 
these have a similar enrichment pattern with the 200 “GW” effects. The “S” effects exhibited a 217 
pattern of enrichment that is similar to the “GW” effects, with only B cell expression reaching a 218 
threshold of statistical significance (Fig. S7). This provides additional circumstantial evidence 219 
that this category of variants may harbor true causal associations. On the other hand, the “NR” 220 
enrichment results seem to follow a rather random pattern, suggesting that most of these effects 221 
are indeed not truly MS-related (Fig. S7).  222 
The strong enrichment of the GW effects in immune cell types motivated us to prioritize 223 
candidate MS susceptibility genes by identifying those susceptibility variants, which affect RNA 224 
expression of nearby genes (cis expression quantitative trait loci effect, cis -eQTL) (±500Kbps 225 
around the effect SNP) (9). Thus, we interrogated the potential function of MS susceptibility 226 
variants in naive CD4+ T cells and monocytes from 211 healthy subjects as well as peripheral 227 
blood mononuclear cells (PBMCs) from 225 remitting relapsing MS subjects. Thirty-six out of 228 
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the 200 GW MS effects (18%) had at least one tagging SNP (r2>=0.5) that altered the expression 229 
of 46 genes (false discovery rate; FDR<5%) in CD4+ naïve T cells (Table S15-S16), and 36 MS 230 
effects (18%; 10 common with the CD4+ naïve T cells) influenced the expression of 48 genes in 231 
monocytes (11 genes in common with T cells). In MS PBMC, 30% of the GW effects (60 out of 232 
the 200) were cis-eQTLs for 92 genes in the PBMC MS samples, with several loci being shared 233 
with those found in healthy T cells and monocytes (26 effects and 27 genes in T cells, and 21 234 
effects and 24 genes in monocytes, respectively; Table S15-S16).  235 
Since MS is a disease of the CNS, we also investigated a large collection of dorsolateral 236 
prefrontal cortex RNA sequencing profiles from two longitudinal cohort studies of aging (n=455), 237 
which recruit cognitively non-impaired individuals (9). This cortical sample provides a tissue- 238 
level profile derived from a complex mixture of neurons, astrocytes, and other parenchymal cells 239 
such as microglia and occasional peripheral immune cells. In these data, we found that 66 of the 240 
GW MS effects (33% of the 200 effects) were cis-eQTLs for 104 genes. Over this CNS and the 241 
three immune sets of data, 104 GW effects were cis-eQTLs for 203 unique genes (n=211 cis- 242 
eQTLs), with several appearing to be seemingly specific for one of the cell/tissue type (Table 243 
S16). Specifically, 21.2% (45 out of 212 cis-eQTLs) of these cortical cis-eQTLs displayed no 244 
evidence of association (p-value>0.05, for linear regression(9), with any SNP with r2>0.1) in the 245 
immune cell/tissue results and are less likely to be immune-related (Table S16-S17).  246 
To further explore the challenging and critical question of whether some of the MS variants 247 
have an effect that is primarily exerted through a non-immune cell, we performed a secondary 248 
analysis of our cortical RNAseq data in which we attempted to ascribe a brain cis-eQTL to a 249 
particular cell type. Specifically, we assessed our tissue-level profile and adjusted each cis-eQTL 250 
analysis for the proportion of neurons, astrocytes, microglia, and oligodendrocytes estimated to 251 
be present in the tissue: the hypothesis was that the effect of a SNP with a cell type-specific cis- 252 
eQTL would be stronger if we adjusted for the proportion of the target cell type (Fig. 6; Fig. S8). 253 
As anticipated, almost all of the MS variants present in cortex remain ambiguous: it is likely that 254 
many of them influence gene function in multiple immune and non-immune cell types. However, 255 
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the SLC12A5 locus is different: here, the effect of the SNP is significantly stronger when we 256 
account for the proportion of neurons (Fig. 6A and 6B), and the CLECL1 locus emerges when we 257 
account for the proportion of microglia. SLC12A5 is a potassium/chloride transporter that is 258 
known to be expressed in neurons, and a rare variant in SLC12A5 causes a form of pediatric 259 
epilepsy (28, 29). While this MS locus may therefore appear to be a good candidate to have a 260 
primarily neuronal effect, further evaluation finds that this MS susceptibility haplotype also 261 
harbors susceptibility to rheumatoid arthritis (30) and a cis-eQTL in B cells for the CD40 gene 262 
(31). Thus, the same haplotype harbors different functional effects in very different contexts, 263 
illustrating the challenge in dissecting the functional consequences of autoimmune variants in 264 
immune function as opposed to the tissue targeted in autoimmune disease. On the other hand, 265 
CLECL1 represents a simpler case of a known susceptibility effect that has previously been 266 
linked to altered CLECL1 RNA expression in monocytes (26, 32); its enrichment in microglial 267 
cells, which share many molecular pathways with other myeloid cells, is more straightforward to 268 
understand. CLECL1 is expressed at low level in our cortical RNAseq profiles because microglia 269 
represent just a small fraction of cells at the cortical tissue level, and its expression level is 20- 270 
fold greater when we compare its level of expression in purified human cortical microglia to the 271 
bulk cortical tissue (Fig. 6). CLECL1 therefore suggests a potential role of microglia in MS 272 
susceptibility, which is under-estimated in bulk tissue profiles that are available in epigenomic 273 
and transcriptomic reference data. Overall, many genes that are eQTL targets of MS variants in 274 
the human cortex are most likely to affect multiple cell types. These brain eQTL results and the 275 
enrichment found in analyses of our purified human microglia data therefore highlight the need 276 
for more targeted, cell-type specific data for the CNS to adequately determine the extent of its 277 
role in MS susceptibility.  278 
These eQTL studies begin to transition our genetic map into a resource outlining the likely 279 
MS susceptibility gene(s) in a locus and the potential functional consequences of certain MS 280 
variants. To assemble these single-locus results into a higher-order perspective of MS 281 
susceptibility, we turned to pathway analyses to evaluate how the extended list of genome-wide 282 
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effects provides new insights into the pathophysiology of the disease. Acknowledging that there 283 
is no available method to identify all causal genes following GWAS discoveries, we prioritized 284 
genes for pathway analyses while allowing several different hypotheses for mechanisms of 285 
actions (9). In brief, we prioritized genes that: (i) were cis-eQTLs in any of the eQTL data sets 286 
outlined above, (ii) had at least one exonic variant at r2>=0.1 with any of the 200 effects, (iii) had 287 
high score of regulatory potential using a cell specific network approach, (iv) had a similar co- 288 
expression pattern as identified using DEPICT.(33) Sensitivity analyses were performed 289 
including different combinations of the above categories, and including genes with intronic 290 
variants at r2>=0.5 with any of the 200 effects (9). Overall, we prioritized 551 candidate MS 291 
genes (Table S18; Table S19 for sensitivity analyses) to test for statistical enrichment of known 292 
pathways. Approximately 39.6% (142 out of 358) of the Ingenuity Pathway Analysis (IPA) 293 
canonical pathways,(34) that had overlap with at least one of the identified genes, were enriched 294 
for MS genes at an FDR<5% (Table S20). Sensitivity analyses including different criteria to 295 
prioritize genes revealed a similar pattern of pathway enrichment (9) (Table S21). Interestingly, 296 
the extensive list of susceptibility genes, that more than doubles the previous knowledge in MS, 297 
captures processes of development, maturation, and terminal differentiation of several immune 298 
cells that potentially interact to predispose to MS. In particular, the role of B cells, dendritic cells 299 
and natural killer cells has emerged more clearly, broadening the prior narrative of T cell 300 
dysregulation that emerged from earlier studies.(4) Given the over-representation of immune 301 
pathways in these databases, ambiguity remains as to where some variants may have their effect: 302 
neurons and particularly astrocytes repurpose the component genes of many “immune” signaling 303 
pathways, such as the ciliary neurotrophic factor (CNTF), nerve growth factor (NGF), and 304 
neuregulin signaling pathways that are highly significant in our analysis (Table S20). These 305 
results – along with the results relating to microglia – emphasize the need for further dissection of 306 
these pathways in specific cell types to resolve where a variant is exerting its effect; it is possible 307 
that multiple, different cell types could be involved in disease since they all experience the effect 308 
of the variant.  309 
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Pathway and gene-set enrichment analyses can only identify statistically significant 310 
connections of genes in already reported, and in some cases validated, mechanisms of action. 311 
However, the function of many genes is yet to be uncovered and, even for well-studied genes, the 312 
full repertoire of possible mechanisms is still incomplete. To complement the pathway analysis 313 
approach and to explore the connectivity of our prioritized GW genes, we performed a protein- 314 
protein interaction (PPI) analysis using GeNets.(9, 35) About a third of the 551 prioritized genes 315 
(n=190; 34.5%) were connected (p-value = 0.052; permutation-based p-value) and these could be 316 
organized into 13 communities, i.e. sub-networks with higher connectivity (p-value: < 0.002; 317 
permutation-based p-value; Table S22). This compares to 9 communities that could be identified 318 
by the previously reported MS susceptibility list (81 connected genes out of 307; Table S23).(3) 319 
Next, we leveraged GeNets to predict candidate genes based on network connectivity and 320 
pathway membership similarity and test whether our previous known MS susceptibility list could 321 
have predicted any of the genes prioritized by the newly identified effects. Of the 244 genes 322 
prioritized by novel findings (out of the 551 overall prioritized genes) only five could be 323 
predicted given the old results (out of 70 candidates that emerge from the extrapolation of earlier 324 
data; Fig. S9 and Table S24). In a similar fashion we estimated that the list of 551 prioritized 325 
genes could predict 102 new candidate genes, four of which can be prioritized since they are in 326 
the list of suggestive effects. (Fig. 1; Fig. S10 and Table S25).    327 
Discussion  328 
This detailed genetic map of MS is a powerful substrate for annotation and functional 329 
studies and provides a new level of understanding for the molecular events that contribute to MS 330 
susceptibility. Although the exact amount of MS’s heritability varies given the data and method 331 
used, (36-38) we report that our findings can explain up to 48% of the heritability that can be 332 
estimated using large-scale GWAS data. It is clear that these events are widely distributed across 333 
the many different cellular components of both the innate and adaptive arms of the immune 334 
system: every major immune cell type is enriched for MS susceptibility genes. An important 335 
caveat is that many of the implicated molecular pathways, such as response to TNFα and type I 336 
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interferons, are repurposed in many different cell types, leading to an important ambiguity: is risk 337 
of disease driven by altered function of only one of the implicated cell types or are all of them 338 
contributing to susceptibility equally? This question highlights the important issue of the context 339 
in which these variants are exerting their effects. We have been thorough in our evaluation of 340 
available reference epigenomic data, but many different cell types and cell states remain to be 341 
characterized and could alter our summary. Further, inter-individual variability has not been 342 
established in such reference data that are typically produced from one or a handful of 343 
individuals; thus, this issue is better evaluated in the eQTL data where we have examined a range 344 
of samples and states in large numbers of subjects. Overall, while we have identified putative 345 
functional consequences for the identified MS variants, the functional consequence of most of 346 
these MS variants requires further investigation.  347 
Even where a function is reported, further work is needed to demonstrate that the effect is 348 
the causal functional change. This is particularly true of the role of the CNS in MS susceptibility: 349 
we mostly have data at the level of the human cortex, a complex tissue with many different cell 350 
types, including resident microglia and a small number of infiltrating macrophage and 351 
lymphocytes. MS variants clearly influence gene expression in this tissue, and we must now: (1) 352 
resolve the implicated cell types and whether pathways shared with immune cells are having their 353 
MS susceptibility effect in the periphery or in the brain and; (2) more deeply identify additional 354 
functional consequences that may be present in only a subset of cells, such as microglia or 355 
activated astrocytes, that are obscured in the cortical tissue level profile. A handful of loci are 356 
intriguing in that they alter gene expression in the human cortex but not in the sampled immune 357 
cells; these MS susceptibility variants deserve close examination to resolve the important 358 
question of the extent to which the CNS is involved in disease onset. Thus, our study suggests 359 
that while MS is a disease whose origin may lie primarily within the peripheral immune 360 
compartment where dysregulation of all branches of the immune system leads to organ specific 361 
autoimmunity, there is subset of loci with a key role in directing the tissue specific autoimmune 362 
response. This is similar to our previous examination of ulcerative colitis, where we observed 363 
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enrichment of genetic variants mapping to colon tissue.(7) This view is consistent with our 364 
understanding of the mechanism of important MS therapies such as natalizumab and fingolimod 365 
that sequester pathogenic immune cell populations in the peripheral circulation to prevent 366 
episodes of acute CNS inflammation. It also has important implications as we begin to consider 367 
prevention strategies to block the onset of the disease by early targeting peripheral immune cells. 368 
An important step forward in MS genetics, for a disease with a 3:1 preponderance of 369 
women being affected, is robust evidence for a susceptibility locus on the X chromosome. 370 
Although chromosome X associations cannot be the sole explanation for the preponderance of 371 
women among MS patients, the discovery of an MS locus on the X chromosome is an exciting 372 
first step towards understanding the genetic contributions of this strong sex bias. This result also 373 
highlights the need for additional, dedicated genetic studies of the sex chromosomes in MS as 374 
existing data have not been fully leveraged. (39) Future studies will also need to incorporate the 375 
interaction of the autosomal genome with factors that can affect the sex bias, e.g. hormones. (40) 376 
This genomic map of MS – the genetic map and its integrated functional annotation - is a 377 
foundation on which the next generation of projects will be developed. It is an important substrate 378 
with which to further dissect the genetic architecture of MS by accounting for the contribution of 379 
sex, evaluating the possibility of interaction among loci and assessing other important factors 380 
such as heterogeneity of effects across human populations or certain subsets of patients given the 381 
heterogeneity of this disease. In the current study we have included individuals with either the 382 
relapsing remitting or the progressive form of MS as they are currently conceptualized to belong 383 
to the same disease spectrum. Further investigation may lead to the identification of variants that 384 
have an effect on the neurodegenerative component of MS, which is largely genetically distinct 385 
from MS susceptibility. (41) Beyond the characterization of the molecular events that trigger MS, 386 
this map will also inform the development of primary prevention strategies since we can leverage 387 
this information to identify the subset of individuals who are at greatest risk of developing MS. 388 
While insufficient by itself, an MS Genetic Risk Score has a role to play in guiding the 389 
management of the population of individuals “at risk” of MS (such as family members) when 390 
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deployed in combination with other measures of risk and biomarkers that capture intermediate 391 
phenotypes along the trajectory from health to disease.(42) We thus report an important milestone 392 
in the investigation of MS and share a roadmap for future work: the establishment of a map with 393 
which to guide the development of the next generation of studies with high-dimensional 394 
molecular data to explore both the initial steps of immune dysregulation across both the adaptive 395 
and innate arms of the immune system and secondly the translation of this auto-immune process 396 
to the CNS where it triggers a neurodegenerative cascade.  397 
Materials and Methods 398 
Detailed materials and methods are listed in the Supplementary Material (9). In brief, we 399 
analyzed genetic data from 15 GWAS of MS. For the autosomal non-MHC genome, we applied a 400 
partitioning approach to create regions of ±1Mbps around the most statistically significant SNP. 401 
Then we performed stepwise conditional analyses within each region to identify statistically 402 
independent effects (n=4,842). We replicated these effects in two large-scale replication cohorts: 403 
i) nine (9) data sets genotyped with the MS Replication Chip, and ii) eleven (11) data sets 404 
genotyped with the ImmunoChip. Chromosomes X and Y were analyzed jointly across all the 405 
data sets, i.e. the discovery and replication. The extended MHC region was also analyzed jointly 406 
across all data sets. We further imputed HLA class I and II alleles and corresponding amino acids. 407 
Statistically independent effects in the autosomal non-MHC genome were group into 4 categories 408 
post-replication: i) genome-wide effects (GW), ii) suggestive effects (S), iii) non-replicated (NR), 409 
and iv) no replication data (ND). Narrow sense heritability was estimated for various 410 
combinations of these effects, and the extended MHC region, to quantify the amount of the 411 
heritability our findings could explain. Next, we leveraged enrichment methods and tissue/cell 412 
reference data sets to characterize the potential involvement of the identified MS effects in the 413 
immune and central nervous system, at the tissue and cellular level. We developed an ensemble 414 
approach to prioritize genes putative associated with the identify effects, leveraging cell-specific 415 
eQTL studies, network approaches, and genomic annotations. Pathway analyses were performed 416 
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to characterize canonical pathways statistically enriched for the putative causal genes. Finally, we 417 
leveraged protein-protein interaction networks to quantify the degree of connectivity of the 418 
putative causal genes and identify new mechanisms of action. 419 
  420 
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Fig. legends: 656 
 657 
Fig. 1. The genetic map of multiple sclerosis. The circos plot displays the 4,842 prioritized 658 
autosomal non-MHC effects and the associations in chromosome X. Joint analysis (discovery and 659 
replication) p-values are plotted as lines (fixed effects inverse-variance meta-analysis). The green 660 
inner layer displays genome-wide significance (p-value<5x10-8), the blue inner layer suggestive 661 
p-values (1x10-5<p-value>5x10-8), and the grey p-values > 1x10-5. Each line in the inner layers 662 
represents one effect. 200 autosomal non-MHC and one in chromosome X genome-wide effects 663 
are listed. The vertical lines in the inner layers represent one effect and the respective color 664 
displays the replication status (see main text and Online Methods): green (genome-wide), blue 665 
(potentially replicated), red (non-replicated). 551 prioritized genes are plotted on the outer 666 
surface. The inner circle space includes protein-protein interactions (PPI) between genome-wide 667 
genes (green), and genome-wide genes and potentially replicated genes (blue) that are identified 668 
as candidates using protein-protein interaction networks (see main text) (9). 669 
 670 
 671 
Fig. 2. Multiple independent effects in the EVI5 locus and chromosome X associations. A) 672 
Regional association plot of the EVI5 locus. Discovery p-values (fixed effects inverse-variance 673 
meta-analysis) are displayed. The layer tagged “Marginal” plots the associations of the marginal 674 
analysis, with most statistically significant SNP being rs11809700 (ORT=1.16; p-value= 3.51x10- 675 
15). The “Step 1” plots the associations conditioning on rs11809700; rs12133753 is the most 676 
statistically significant SNP (ORC=1.14; p-value= 8.53x10-09). “Step 2” plots the results 677 
conditioning on rs11809700 and rs12133753, with rs1415069 displaying the lowest p-value 678 
(ORG=1.10; p-value= 4.01x10-5). Finally, “Step 3” plots the associations conditioning on 679 
rs11809700, rs12133753, and rs1415069, identifying rs58394161 as the most-statistically 680 
significant SNP (ORC=1.10; p-value= 8.63x10-4). All 4 SNPs reached genome-wide significance 681 
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in the respective joint, discovery plus replication, analyses (Table S7). Each of the independent 4 682 
SNPs, i.e. lead SNPs, are highlighted using a triangle in the respective layer. B) Regional 683 
association plot for the genome-wide chromosome X variant. Joint analysis p-values (fixed 684 
effects inverse-variance meta-analysis) are displayed. Linkage disequilibrium, in terms of r2 based 685 
on the 1000 Genomes European panel, is indicated using a combination of color grade and 686 
symbol size (see legend for details). All positions are in human genome 19.   687 
 688 
 689 
Fig. 3. Independent associations in the major histocompatibility locus. Regional association 690 
plot in the MHC locus. Only genome-wide statistically independent effects are listed. The order 691 
of variants in the X-axis represents the order these were identified. The size of the circle 692 
represents different values of –log10(p-value) (fixed effects inverse-variance meta-analysis). 693 
Different colors are used to depict class I, II, III, and non-HLA effects. Y-axis displays million 694 
base pairs. 695 
 696 
Fig. 4. Heritability partitioning. Proportion of the overall narrow-sense heritability under the 697 
liability model (~19.2%) explained by different genetic components. (A) The overall heritability 698 
is partitioned in the super extended MHC (SE MHC), the 1,962 Regions that include all SNPs 699 
with p-value<0.05 (Regions; fixed effects inverse-variance meta-analysis), and the rest of genome 700 
with p-values>0.05 (Non-associated regions). (B) The Regions are further partitioned to the 701 
seemingly statistically independent effects (Prioritized) and the residual (Non-prioritized).  (C) 702 
The Prioritized component is partitioned based on the replication knowledge to genome-wide 703 
effects (GW), suggestive (S), non-replicated (ND), and no data (ND). The lines connecting the 704 
pie charts depict the component that is partitioned. All values are estimated using the discovery 705 
data-sets (n= 4,802 cases and 26,703 controls).  706 
 707 
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Fig. 5. Tissue and cell type enrichment analyses. (A) Gene Atlas tissues and cell types gene 708 
expression enrichment. (B) DNA hypersensitivity sites (DHS) enrichment for tissues and cell 709 
types from the NIH Epigenetic Roadmap. Rows are sorted from immune cells/tissues to central 710 
nervous system related ones. Both X axes display –log10 of Benjamini & Hochberg p-values 711 
(false discovery rate).     712 
 713 
 714 
Fig. 6. Dissection of cortical RNAseq data. In (A), we present a heatmap of the results of our 715 
analysis assessing whether a cortical eQTL is likely to come from one of the component cell 716 
types of the cortex: neurons, oligodendrocytes, endothelial cells, microglia and astrocytes (in 717 
rows). Each column presents results for one of the MS brain eQTLs. The color scheme relates to 718 
the p-value of the interaction term (linear regression), with red denoting a more extreme result. 719 
(B) We present the same results in a different form, comparing results of assessing for interaction 720 
with neuronal proportion (y axis) and microglial proportion (x-axis): the SLC12A5 eQTL is 721 
significantly stronger when accounting for neuronal proportion, and CLECL1 is significantly 722 
stronger when accounting for microglia. The Bonferroni-corrected threshold of significance is 723 
highlighted by the dashed line. (C) Locus view of the SLC12A5/CD40 locus, illustrating the 724 
distribution of MS susceptibility and the SLC12A5 brain eQTL in a segment of chromosome 20 725 
(x axis); the y axis presents the p-value of association with MS susceptibility (top panel; fixed 726 
effects inverse-variance meta-analysis) or SLC12A5 RNA expression (bottom panel; linear 727 
regression). The lead MS SNP is denoted by a triangle, other SNPs are circles, with the intensity 728 
of the red color denoting the strength of LD with the lead MS SNP in both panels. (D) Here we 729 
plot the level of expression, transcriptome-wide, for each measured gene in our cortical RNAseq 730 
dataset (n=455)(y-axis) and purified human microglia (n=10)(x-axis) from the same cortical 731 
region. In blue, we highlight those genes with > 4 fold increased expression in microglia relative 732 
to bulk cortical tissue and are expressed at a reasonable level in microglia. Each dot is one gene. 733 
Gray dots denote the 551 putative MS genes from our integrated analysis. SLC12A5 and CLECL1 734 
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are highlighted in red; in blue, we highlight a selected subset of the MS genes – many of them 735 
well-validated – which are enriched in microglia. For clarity, we did not include all of the MS 736 
genes that fall in this category.   737 
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